Tyrosine Kinase Inhibitors: all 10,469 studies that test it

Page 32 of 105. Open to participants first (1,907), then studies with results posted, then the rest; newest registration first within each.

• Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.TerminatedNCT02335944Phase 1/2Results posted
• Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin LymphomasCompletedNCT02332980Phase 2Results posted
• Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)CompletedNCT02329860Phase 3Results posted
• A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic MalignanciesCompletedNCT02329847Phase 1/2Results posted
• FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB ExpressionCompletedNCT02325739Phase 1/2Results posted
• Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung CancerTerminatedNCT02323126Phase 2Results posted
• Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)TerminatedNCT02323113Phase 1/2Results posted
• TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet ChemotherapyTerminatedNCT02322281Phase 3Results posted
• Musculoskeletal Ultrasound Assessment of Therapeutic Response of Tofacitinib in Rheumatoid Arthritis PatientsCompletedNCT02321930Phase 4Results posted
• A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung CancerCompletedNCT02321540Phase 1/2Results posted
• Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung CancerCompletedNCT02317016Phase 1Results posted
• Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive SurgeryTerminatedNCT02315625Phase 2Results posted
• Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT02315430Phase 2Results posted
• Tofacitinib for the Treatment of Alopecia Areata and Its VariantsCompletedNCT02312882Not applicableResults posted
• Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CMLCompletedNCT02311998Phase 1/2Results posted
• A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect InvestigationCompletedNCT02310750Phase 1Results posted
• A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.CompletedNCT02310321Phase 1/2Results posted
• A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDsCompletedNCT02308163Phase 3Results posted
• A Study to Evaluate Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to Methotrexate (MTX) TreatmentCompletedNCT02305849Phase 3Results posted
• Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin LymphomaCompletedNCT02303392Phase 1Results posted
• Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by SurgeryCompletedNCT02302833Phase 2Results posted
• Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for ChemotherapyCompletedNCT02300545Phase 2Results posted
• Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line ChemotherapyCompletedNCT02300298Phase 1Results posted
• Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And UniversalisCompletedNCT02299297Phase 2Results posted
• Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung CancerCompletedNCT02299141Phase 2Results posted
• Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating DasatinibCompletedNCT02297139Phase 2Results posted
• Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast CancerTerminatedNCT02294786Phase 2Results posted
• Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.CompletedNCT02292446Phase 3Results posted
• A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid ArthritisCompletedNCT02281552Phase 3Results posted
• Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube CancerTerminatedNCT02278783Phase 2Results posted
• Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal CancerTerminatedNCT02277093Phase 2Results posted
• A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung CancerCompletedNCT02276027Phase 2Results posted
• Phase 1 Study of E7090 in Subjects With Solid TumorCompletedNCT02275910Phase 1Results posted
• Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the LiverCompletedNCT02273362Phase 1/2Results posted
• Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.CompletedNCT02272998Phase 2Results posted
• A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic PhaseCompletedNCT02272777Phase 3Results posted
• Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell LymphomaTerminatedNCT02272686Phase 2Results posted
• The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant SettingTerminatedNCT02271906Phase 2Results posted
• The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)CompletedNCT02269267Phase 2Results posted
• Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)CompletedNCT02267278Phase 2Results posted
• A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA)CompletedNCT02265705Phase 3Results posted
• An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced MalignanciesTerminatedNCT02265510Phase 1/2Results posted
• Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 FusionsCompletedNCT02265341Phase 2Results posted
• A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)CompletedNCT02264574Phase 3Results posted
• Icotinib for Completed Resected IB NSCLC With EGFR MutationCompletedNCT02264210Phase 2Results posted
• A Study of Baricitinib in Healthy Japanese ParticipantsCompletedNCT02263911Phase 1Results posted
• Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain MetastasesCompletedNCT02260531Phase 2Results posted
• Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine TumorsCompletedNCT02259725Phase 2Results posted
• BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)CompletedNCT02257541Phase 1/2Results posted
• Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid LeukemiaCompletedNCT02257138Phase 1/2Results posted
• JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary MyelofibrosisCompletedNCT02251821Phase 2Results posted
• A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic LeukemiaActive, not recruitingNCT02251548Phase 2Results posted
• Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing SarcomaActive, not recruitingNCT02243605Phase 2Results posted
• Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell LymphomaCompletedNCT02242097Phase 2Results posted
• Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI CancersTerminatedNCT02241720Phase 2Results posted
• A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast CancerCompletedNCT02236000Phase 1/2Results posted
• A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar CarcinomaCompletedNCT02234986Phase 2Results posted
• Nintedanib in Patients With Advanced Esophagogastric CancerCompletedNCT02234596Phase 2Results posted
• Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and SurgeryTerminatedNCT02234180Phase 2Results posted
• LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational ResearchTerminatedNCT02231164Phase 3Results posted
• Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase InhibitorsTerminatedNCT02228382Phase 4Results posted
• Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy VolunteersCompletedNCT02224053Phase 1Results posted
• Crizotinib in High-Risk Uveal Melanoma Following Definitive TherapyCompletedNCT02223819Phase 2Results posted
• Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular DegenerationTerminatedNCT02222207Phase 2Results posted
• An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell LymphomaActive, not recruitingNCT02213926Phase 2Results posted
• Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast CancerTerminatedNCT02213042Phase 2Results posted
• Evaluation of Votrient in AngiosarcomaTerminatedNCT02212015Phase 2Results posted
• An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple MyelomaCompletedNCT02211014Phase 1Results posted
• Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) MutationCompletedNCT02208843Phase 4Results posted
• Pazopanib Maintenance Phase IITerminatedNCT02207309Phase 2Results posted
• Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin LymphomaCompletedNCT02207062Phase 2Results posted
• Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic TelangiectasiaTerminatedNCT02204371Phase 2Results posted
• A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast CancerTerminatedNCT02202746Phase 2Results posted
• Study to Evaluate PF-04965842 in Patients With Moderate to Severe PsoriasisTerminatedNCT02201524Phase 2Results posted
• Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLCCompletedNCT02197247Phase 1Results posted
• Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLCCompletedNCT02197234Phase 1Results posted
• Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD MutationCompletedNCT02196857Phase 2Results posted
• Study of Fruquintinib in Patients With Metastatic Colorectal CancerCompletedNCT02196688Phase 2Results posted
• Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck CancerTerminatedNCT02196168Phase 2Results posted
• Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host DiseaseCompletedNCT02195869Phase 1/2Results posted
• Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver MetastasesCompletedNCT02195011Phase 2Results posted
• Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by SurgeryCompletedNCT02194829Phase 1/2Results posted
• Pazopanib in Molecularly Selected Patients With Advanced NSCLCTerminatedNCT02193152Phase 2Results posted
• Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)CompletedNCT02191891Phase 1Results posted
• Nintedanib in Volunteers With Hepatic Impairment Compared With Healthy VolunteersCompletedNCT02191865Phase 1Results posted
• An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With MethotrexateCompletedNCT02187055Phase 4Results posted
• Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)TerminatedNCT02186821Phase 2Results posted
• Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by SurgeryCompletedNCT02180867Phase 2/3Results posted
• An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström MacroglobulinemiaActive, not recruitingNCT02180724Phase 2Results posted
• Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin LymphomaActive, not recruitingNCT02180711Phase 1/2Results posted
• Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung CancerCompletedNCT02179671Phase 2Results posted
• A Study of LY2157299 in Participants With Advanced Hepatocellular CarcinomaCompletedNCT02178358Phase 2Results posted
• [18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to RegorafenibCompletedNCT02175095Not applicableResults posted
• Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing SurgeryTerminatedNCT02169284Phase 2Results posted
• Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic CancerTerminatedNCT02168777Phase 1Results posted
• A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's DiseaseCompletedNCT02167256Phase 2Results posted
• Ibrutinib With Rituximab in Adults With Waldenström's MacroglobulinemiaCompletedNCT02165397Phase 3Results posted
• Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GISTCompletedNCT02164240Phase 1Results posted
• Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung CancerCompletedNCT02163733Phase 1Results posted
• BGJ398 for Patients With Tumors With FGFR Genetic AlterationsTerminatedNCT02160041Phase 2Results posted

← Tyrosine Kinase Inhibitors overview